Clinical trials: Metastatic Neoplasm
Neuroendocrine Tumors
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas…
- Trial name
- TALENT (NCT02678780)
- Testing
- Lenvatinib
- Where
- 22 sites in Austria, Italy and 2 more
- Volunteers
- 123 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Pancreatic Adenocarcinoma
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
This study is a prospective, open-label, randomized controlled trial that enrolled previously untreated patients with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT06789679
- Testing
- Gemcitabine, albumin-bound paclitaxel, S-1, Gemcitabine, albumin-bound paclitaxel
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Adenocarcinoma Metastatic in the Liver
Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases
This is a single-center, open-label, exploratory phase II trial to evaluate efficacy and safety of Retlirafusp alfa (PD-L1/TGF-βRII bispecific fusion protein) combined with standard first-line targeted-chemotherapy as conversion…
- Trial name
- NCT07815288
- Testing
- Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Melanoma
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.
- Trial name
- NCT02141542
- Testing
- Tremelimumab, MEDI3617
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- F. Stephen Hodi, MD
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Liver Metastases
Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases
Background: Anatomical (traditional) stereotactic body radio therapy(SBRT) treatment planning assumes homogenous distribution of function in the normal liver tissue.
- Trial name
- NCT01861873
- Testing
- measuring liver function by 18-FDGal PET/CT
- Where
- Denmark
- Volunteers
- 28 people
- Sponsor
- University of Aarhus
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
- Trial name
- RECAP (NCT01423604)
- Testing
- Capecitabine, Ruxolitinib
- Where
- 39 sites in United States
- Volunteers
- 136 people
- Sponsor
- Incyte Corporation
Labor Stage, Second
Obstetrical Gel Use to Shorten Labor and Prevent Lower Genital Tract Trauma
Recent literature shows that birth injury is associated with postpartum pelvic floor dysfunction (pelvic organ prolapse and fecal and urinary incontinence).
- Trial name
- NCT03518684
- Testing
- Natalis
- Where
- Lebanon
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- American University of Beirut Medical Center
Nasopharyngeal Carcinoma
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Hypothesis We hypothesise that intermittent dosing of the anti-angiogenic RTKI sunitinib or bevacizumab prior to systemic cisplatin and gemcitabine chemotherapy to transiently "normalise" tumour vasculature in patients with…
- Trial name
- NCT01309633
- Testing
- 12.5mg sunitinib with Cisplatin and Gemcitabine, 25mg Sunitinib alternating with Cisplatin and Gemcitabine, 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
Leukemia, Myelodysplastic Syndromes
S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00996047
- Testing
- cytogenetic analysis, fluorescence in situ hybridization
- Where
- 280 sites in United States
- Volunteers
- 3,341 people
- Sponsor
- SWOG Cancer Research Network
Liver Metastasis Colon Cancer
Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools
This study will demonstrate the diagnostic utility of PSMA PET among patients with CRC with liver metastasis.
- Trial name
- PSMA (NCT06935149)
- Testing
- 18-PSMA
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Primo Biotechnology Co., Ltd
Malignant Melanoma Stage IV, BRAF V600 Mutation
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
This is a phase II, open label, non-randomised study of vemurafenib and cobimetinib after radiosurgery in adult patients with BRAFV600-mutant melanoma brain metastases.
- Conditions
- Malignant Melanoma Stage IV, BRAF V600 Mutation, Brain Metastases
- Trial name
- RadioCoBRIM (NCT03430947)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Technische Universität Dresden
Prostate Neoplasm
Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Radioligand therapy (RLT) using Lu-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer.
- Trial name
- NCT03828838
- Testing
- Lu-177 PSMA-617
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Metastatic Renal Cell Carcinoma
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when…
- Trial name
- SUNRISES (NCT01784978)
- Testing
- Sunitinib, Everolimus
- Where
- 10 sites in France, Greece and 1 more
- Volunteers
- 41 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00792025
- Testing
- sunitinib malate
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Institut Curie
Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV
A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer
RATIONALE: Recently, the importance of prognosis according to the location of the primary tumor in colorectal cancer has been raised.
- Trial name
- NCT03641976
- Testing
- A-FOLFOXIRI, Arm II (A-FOLFOX/A-FOLFIRI)
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Yonsei University
Bone Metastases, HER2-positive Breast Cancer
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine in…
- Conditions
- Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases
- Trial name
- NCT02226276
- Testing
- fludeoxyglucose F 18, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
ALK-positive Non-small Cell Lung Cancer, Brain Metastases
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
This study was a retrospective observational study. The study included patients with non-small cell lung cancer with ALK-fusion brain metastases or meningeal metastases who received first-line and late-line treatment with the…
- Conditions
- ALK-positive Non-small Cell Lung Cancer, Brain Metastases, Meningeal Metastasis
- Trial name
- NCT06410040
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Metastatic Colorectal Cancer
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
This study will be looking at whether CY/GVAX in combination with SGI-110 is effective (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and safe in patients with metastatic colon or rectum…
- Trial name
- NCT01966289
- Testing
- CY, GVAX, SGI-110
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sarcoma, Soft Tissue
Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)
The goal of this trial is to determine whether oral continuous (metronomic) therapy with trofosfamide results in a similar rate of progression-free time after 6 months as intravenous treatment with adriamycin.
- Trial name
- NCT00204568
- Testing
- Adriamycin, Trofosfamide
- Where
- Germany
- Volunteers
- 117 people
- Sponsor
- University Hospital Schleswig-Holstein
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.